SOCRA CCRP Monitor 2 — Questions and Answers
Question 1: What is the primary purpose of source data verification (SDV) during a monitoring visit?
- To verify the site's financial records
- To ensure that data recorded in the CRF accurately reflects the source documents (Correct answer)
- To train site staff on the protocol
- To audit the sponsor's clinical database
Correct answer: To ensure that data recorded in the CRF accurately reflects the source documents
Source data verification is the process by which the monitor compares CRF entries against original source documents to ensure accuracy, completeness, and consistency of reported data.
Source data verification (SDV) is a fundamental monitoring activity defined in ICH-GCP Section 5.18.4. During SDV, the clinical research associate (CRA) compares data entered into the CRF (paper or electronic) against the original source documents (hospital charts, lab reports, radiology reports, pharmacy logs, etc.) to verify that data has been accurately and completely transcribed. SDV helps detect transcription errors, missing data, and potential fraud. While 100% SDV was historically the standard, modern risk-based monitoring approaches may reduce SDV to critical data points and use centralized statistical monitoring to detect data anomalies across sites.
Question 2: According to ICH-GCP, how often should a monitor visit a clinical trial site?
- Once at the beginning and once at the end of the trial
- Monthly, as specified by regulation
- With a frequency determined by the monitoring plan based on trial characteristics (Correct answer)
- Only when the site reports a serious adverse event
Correct answer: With a frequency determined by the monitoring plan based on trial characteristics
ICH-GCP does not mandate a specific visit frequency. Instead, the monitoring plan should define visit frequency based on factors such as trial complexity, enrollment rate, data quality, and site experience.
ICH-GCP Section 5.18.3 states that the monitor should have sufficient qualifications, training, and information to adequately monitor the trial, and Section 5.18.6 discusses the monitoring plan. Visit frequency is determined by the monitoring plan and depends on multiple factors: enrollment rate, trial complexity, site experience, query rates, protocol deviation frequency, and the risk profile of the investigational product. ICH-GCP E6(R2) Addendum Section 5.18.3 emphasizes risk-based monitoring, where sites with higher risk indicators receive more frequent visits. Between on-site visits, monitors may conduct remote or centralized monitoring activities to supplement oversight.
Question 3: What should a monitor do if they discover a serious protocol deviation during a site visit?
- Ignore it if it does not affect subject safety
- Document the deviation, discuss it with the investigator, and report it to the sponsor promptly (Correct answer)
- Close the site immediately without discussion
- Wait until the next monitoring visit to address it
Correct answer: Document the deviation, discuss it with the investigator, and report it to the sponsor promptly
When a serious protocol deviation is discovered, the monitor must document it in the monitoring report, discuss it with the investigator to determine the cause and implement corrective action, and promptly report it to the sponsor.
ICH-GCP Section 5.18.4(e) requires that the monitor report deviations from the protocol, SOPs, GCP, and applicable regulatory requirements to the investigator and take appropriate action to prevent recurrence. The monitor should: (1) document the deviation thoroughly in the monitoring report, (2) discuss the finding with the investigator and site staff to understand the root cause, (3) ensure appropriate corrective and preventive actions (CAPAs) are implemented, (4) follow up on previously identified deviations, and (5) report findings promptly to the sponsor. Serious deviations may require expedited reporting to the IRB/IEC and regulatory authorities. The monitor should also assess whether the deviation compromised subject safety or data integrity.
Question 4: What is a site initiation visit (SIV) and when does it occur?
- A visit to assess site feasibility before the trial begins
- A visit conducted after regulatory approval to train site staff and ensure readiness to enroll subjects (Correct answer)
- A visit to close out the site at the end of the trial
- A routine monitoring visit during the enrollment phase
Correct answer: A visit conducted after regulatory approval to train site staff and ensure readiness to enroll subjects
A site initiation visit occurs after all regulatory approvals are in place and before the first subject is enrolled. Its purpose is to train site staff, review the protocol, verify site readiness, and ensure all essential documents are in place.
The site initiation visit (SIV) is a critical milestone that takes place after the site has received IRB/IEC approval and regulatory authorization but before the first subject is enrolled. During the SIV, the monitor: (1) trains the investigator and site staff on the protocol, CRF completion, study procedures, and GCP requirements, (2) reviews the informed consent process, (3) verifies that all essential regulatory documents are in place, (4) confirms investigational product storage and handling procedures, (5) reviews the laboratory manual and sample handling, (6) verifies that the site has adequate facilities and equipment, and (7) establishes communication channels and reporting procedures. A successful SIV is typically a prerequisite for activating the site to begin enrollment.
Question 5: What is the monitor's responsibility regarding investigational product accountability at a site?
- Only the pharmacist is responsible for drug accountability
- The monitor must verify that the IP is properly stored, dispensed, and accounted for according to the protocol (Correct answer)
- The monitor only needs to count unused drug at the end of the trial
- Drug accountability is the sponsor's sole responsibility
Correct answer: The monitor must verify that the IP is properly stored, dispensed, and accounted for according to the protocol
The monitor is responsible for verifying at each visit that the investigational product is properly stored at required conditions, dispensed correctly according to the protocol, accurately documented on accountability logs, and that unused product is handled appropriately.
ICH-GCP Section 5.18.4(g) specifically requires the monitor to verify that the investigational product is being stored, dispensed, and accounted for according to the protocol and applicable regulatory requirements. During each monitoring visit, the monitor should: (1) review IP accountability logs and reconcile quantities received, dispensed, returned, and remaining, (2) verify proper storage conditions (temperature logs, refrigerator monitoring), (3) check expiry dates, (4) confirm that IP was dispensed to the correct subjects at the correct doses, (5) verify proper randomization procedures were followed if applicable, and (6) ensure that unused or returned IP is handled appropriately (e.g., returned to sponsor or destroyed per protocol). Any discrepancies must be investigated and resolved.
Question 6: What is the difference between triggered and routine monitoring visits?
- There is no difference; all visits are the same
- Routine visits are scheduled per the monitoring plan; triggered visits are unscheduled visits prompted by specific concerns or events (Correct answer)
- Triggered visits are only conducted by auditors, not monitors
- Routine visits are only for data collection while triggered visits are for regulatory inspections
Correct answer: Routine visits are scheduled per the monitoring plan; triggered visits are unscheduled visits prompted by specific concerns or events
Routine monitoring visits are pre-planned visits scheduled according to the monitoring plan, while triggered visits are unscheduled visits initiated in response to specific events such as safety signals, high deviation rates, or enrollment concerns.
Routine monitoring visits are scheduled in advance according to the monitoring plan and occur at regular intervals determined by factors like enrollment rate, trial complexity, and site performance. They cover standard monitoring activities including SDV, document review, and IP accountability. Triggered visits, also called for-cause visits, are unscheduled and initiated in response to specific concerns such as: unexpected safety signals, high rates of protocol deviations or data queries, enrollment irregularities, whistleblower reports, suspicious data patterns identified through centralized monitoring, or serious adverse event follow-up. Triggered visits are typically more focused and may involve more intensive data review in the area of concern. Both types must be documented in monitoring visit reports.
SOCRA CCRP Monitor 2
What is the primary purpose of source data verification (SDV) during a monitoring visit?